I am grateful to have trained at such an incredible center during my graduate school years. Marc’s contributions at the helm of the CFI cannot be understated. Thank you Marc, for your service and leadership!

I am very grateful for the team we have and look forward to getting the next few of these out the door! We are not done yet! Though it may be a hot minute before the next one comes out. Hopefully pre-prints soon at least! Stay tuned! 11/end

We believe these data will be food for thought for folks interested in using our in vivo labeling. And maybe just a fun read for folks who are lymphatic drainage enthusiasts. Big congrats to the lab for closing out our second paper! 10/n

In short, BB700 was the big winner. It continuously labeled for over 6 hours in vivo (crazy right???). Applying it to a transplantable tumor model, we found we could identify roughly 7-fold more tumor specific CD8s that had recently migrated compared to IV administration. 9/n

Because antibody could be found in the plasma for a while, we speculated we could try and find fluorophores that were capable of labeling at low concentrations. This may provide an opportunity to extend the labeling window for rare events! So that’s what we did with serial dilution experiments. 8/n

We next developed a homegrown ELISA to quantify circulating CD45.2 IV and IP antibodies. We saw that IP anti-CD45.2 concentration gradually increased over an hour, while IV disappeared. 7/n

Moreover, when we examined leukocyte labeling in blood contiguous compartments like the red pulp of the spleen, liver, and bone marrow, we found that IP antibody labeling intensity increased over the course of an hour, suggesting that labeling was continuously happening. 6/n

We find that IP injection of anti-CD45.2 antibody does not label cells in the blood as quickly as an IV injection (duh, I know! But still!). IV injection labels all circulating cells within a minute. Whereas we do not get full labeling by IP injection for at least 10 minutes. 5/n

There are a good number of studies looking at this, dating way back to the 40s and 50s. This one from the 80s is particularly well done in my opinion (academic.oup.com/jnci/article...). Don’t feel like reading? IP and IV are different! 4/n

Have you ever wondered about how injecting antibodies via intravenous (IV) or intraperitoneal (IP) injection differs? As a field, we often use IP injection for antibody treatments, and I have always found this to be interesting to think through how IP vs IV injectioun routes may be different. 3/n

One of our big limitations was that it was hard to track rare migration events due to a limited labeling window. More on that in a second. 2/n

Dorian McGavern at NIH had a paper last year using them - www.nature.com/articles/s41...

Keep your eyes peeled for #2 (jimmunol.bsky.social). And submitted our first big kid grants. Hoping for some kindness from reviewers... Very excited to see what things will look like in another year! What a whirlwind of a job - 2 years have flown by! Feeling both lucky and privileged.